Karin (1965) studied Chemistry at the Free University in Amsterdam and specialised in Antropogenetics, Biochemistry and Molecular Biology. She was asked for and accepted a position as PhD student at the department of Biochemistry and Molecular Biology.
The knowledge she gathered formed a solid base to start a career as Senior Biotechnology Analyst at ABN Amro, a position that she held from 2000-2004. In that role she performed analyses for the Biotechnology Fund, the Pharma Fund as well as the regional funds.
At the end of 2004 she joined Robeco as Senior Portfolio Manager Health Care. Beside her day-to-day activities for the Health Care Fund, she was also involved in supporting the Private Equity Department concerning Life Science Investments.
In September 2011, Karin started a company -Key2Bio- that provides research for Biotechnological Investments.
